Published in J Control Release on May 18, 2004
Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol (2010) 1.12
Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int J Pharm Investig (2011) 0.97
Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis (2007) 0.92
Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia (2008) 0.87
Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Curr Med Chem (2012) 0.78
Therapeutic actions of curcumin in bone disorders. Bonekey Rep (2016) 0.77
The role of surface charge in the desolvation process of gelatin: implications in nanoparticle synthesis and modulation of drug release. Int J Nanomedicine (2017) 0.75
Anti-cancerous effect of albumin coated silver nanoparticles on MDA-MB 231 human breast cancer cell line. Sci Rep (2017) 0.75
Polo-like kinases and oncogenesis. Oncogene (2005) 2.86
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol (2008) 2.37
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle (2010) 2.18
Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release (2009) 2.09
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle (2009) 1.75
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 1.55
Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer (2004) 1.54
Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem (2004) 1.52
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene (2002) 1.48
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm (2004) 1.41
Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release (2011) 1.37
Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm (2008) 1.33
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol (2002) 1.32
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst (2004) 1.29
T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity (2010) 1.29
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials (2006) 1.20
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett (2007) 1.20
Human serum albumin-polyethylenimine nanoparticles for gene delivery. J Control Release (2003) 1.20
Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release (2006) 1.18
N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol (2009) 1.16
Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1. Mol Cell Biol (2010) 1.13
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun (2011) 1.12
Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem (2009) 1.11
Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle (2006) 1.10
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res (2006) 1.10
Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials (2005) 1.10
Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm (2009) 1.10
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol (2009) 1.09
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res (2006) 1.09
Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem (2008) 1.08
Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target (2004) 1.08
Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm (2009) 1.06
Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target (2010) 1.05
A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem (2009) 1.04
Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem (2005) 1.03
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer (2008) 1.03
Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One (2012) 1.02
The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer (2005) 1.00
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells. Cell Cycle (2007) 1.00
A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem (2008) 1.00
Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials (2005) 0.99
Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One (2011) 0.99
Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int J Pharm (2008) 0.98
Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target (2006) 0.98
Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target (2010) 0.97
Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia (2010) 0.97
Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomedicine (2011) 0.96
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2007) 0.95
SKAP1 protein PH domain determines RapL membrane localization and Rap1 protein complex formation for T cell receptor (TCR) activation of LFA-1. J Biol Chem (2011) 0.95
Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene (2005) 0.95
Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res (2002) 0.95
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol (2010) 0.95
Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem (2009) 0.93
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target (2009) 0.93
Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Control Release (2011) 0.93
Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res (2006) 0.93
Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res (2008) 0.93
Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS One (2010) 0.92
The biological relevance of FHL2 in tumour cells and its role as a putative cancer target. Anticancer Res (2007) 0.91
Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nat Protoc (2007) 0.91
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials (2009) 0.90
Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations. J Photochem Photobiol B (2009) 0.90
Marine sponge collagen: isolation, characterization and effects on the skin parameters surface-pH, moisture and sebum. Eur J Pharm Biopharm (2002) 0.90
Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials (2008) 0.90
Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay. Proc Natl Acad Sci U S A (2009) 0.90
Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul (2006) 0.90
Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm (2010) 0.89
STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR. Anticancer Res (2005) 0.88
Ethylcellulose: a new type of emulsion stabilizer. Eur J Pharm Biopharm (2003) 0.88
Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release (2005) 0.87
Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm (2010) 0.87
Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target (2006) 0.87
Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia (2008) 0.87
Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur J Pharm Biopharm (2013) 0.87
Demands on caring relatives of head and neck cancer patients. Laryngoscope (2007) 0.86
Adaptor SKAP-55 binds p21 activating exchange factor RasGRP1 and negatively regulates the p21-ERK pathway in T-cells. PLoS One (2008) 0.85
Oligonucleotide-protamine-albumin nanoparticles: Protamine sulfate causes drastic size reduction. J Control Release (2005) 0.85
Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. Int J Pharm (2011) 0.84
Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J Control Release (2004) 0.84
Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. Eur J Pharm Biopharm (2005) 0.84
Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. Pathol Res Pract (2005) 0.83
Degradation of microvascular brain endothelial cell beta-catenin after co-culture with activated neutrophils from patients undergoing cardiac surgery with prolonged cardiopulmonary bypass. Biochem Biophys Res Commun (2005) 0.83
Adsorption of obidoxime onto human serum albumin nanoparticles: drug loading, particle size and drug release. J Microencapsul (2010) 0.82